Models
TORRENT PHARMACEUTICALS LTORNTPHARMPharmaceuticals & Biotechnology
1,285per share · Base Model Note
Revenue growth, the horizon and scenarios are yours to change. Every other input is part of the Trader plan; saving, sharing a saved link and the live-formula workbook are part of the Institutional plan.
Scenario
Value per share, your model1,285implied FY26 P/E 20.5× · EV/EBITDA 12.8×
Against CMP ₹4,965.5074.1%close of 2026-09-10
Growth the CMP implies45.0%revenue, a year for 5 years, on your other inputs
Value after FY3177%share of enterprise value in the terminal
This figure is the arithmetic of your inputs and nothing else. MarketPing publishes no fair value, target or rating; the model is yours.

Where the methods land · ₹ per share · the dashed line is the CMP

DCF, rate ±1 · growth ±1your model across the sensitivity grid
9002,052
52-week rangetraded range, a fact not a value
3,4815,250

From enterprise to equity · ₹ crore

PV of FY27FY31 free cash flow13,252
PV of terminal value43,921
Enterprise value57,173
less net debt(13,681)
less non-controlling interest0
add non-operating investments0
Equity value43,492
÷ 33.85 crore shares1,285
77% of the value sits after FY31. Usual when return on capital sits near the cost of capital; the 5 explicit years carry little of it.

Free cash flow, filed and modelled · ₹ '000 crore

012345FY21: ₹1,676 croreFY21FY22: ₹1,600 croreFY22FY23: ₹1,794 croreFY23FY24: ₹2,833 croreFY24FY25: ₹1,974 croreFY25FY26: ₹2,346 croreFY26FY27: ₹2,756 croreFY27FY28: ₹3,101 croreFY28FY29: ₹3,467 croreFY29FY30: ₹3,846 croreFY30FY31: ₹4,229 croreFY31
Filed, cash from operations − capexModelled free cash flow to firm

Sensitivity · ₹ per share

Down Across
WACCterminal growth4.0%4.5%5.0%5.5%6.0%
10.00%1,3411,4701,6261,8152,052
10.50%1,2051,3131,4401,5921,778
11.00%1,0891,1791,2851,4101,559
11.50%9881,0651,1541,2581,380
12.00%9009671,0421,1291,231
The outlined cell is your model. Green figures sit above the CMP of ₹4,965.50; n/a marks a terminal growth at or above the discount rate. Steps: WACC and terminal growth ±0.5 point, growth ±2, margin ±1.

Distribution of outcomes · 4,000 draws · growth, margin and the discount rate vary together

P10877P501,261P901,747
10th · 50th · 90th percentile, ₹ per share877 · 1,261 · 1,747
Draws below the CMP100%
Rank correlation with ebitda margin+0.76
Rank correlation with discount rate0.45
Rank correlation with revenue growth+0.40
Each driver is drawn from a PERT distribution between the lowest and highest value across your scenarios (or ±50% growth, ±20% margin when there is one scenario), with the discount rate ±1.5 points. Seeded, so the same inputs give the same picture.

Projected cash flow to the firm · ₹ crore

History Forward
₹ croreFY23FY24FY25FY26FY27FY28FY29FY30FY31
Revenue9,62010,72811,51613,98016,98620,63825,07530,46637,016
growth %13.111.57.321.421.521.521.521.521.5
EBITDA2,8423,4563,6974,4705,4356,6048,0249,74911,845
margin %29.532.232.132.032.032.032.032.032.0
less depreciation(707)(808)(795)(1,119)(1,359)(1,651)(2,006)(2,437)(2,961)
EBIT2,1352,6482,9023,3514,0774,9536,0187,3128,884
less tax on EBIT(858)(1,044)(1,268)(1,541)(1,872)(2,274)
NOPAT2,4933,0333,6854,4775,4406,610
add depreciation7078087951,1191,3591,6512,0062,4372,961
less capex(574)(433)(611)(677)(815)(1,238)(1,805)(2,559)(3,554)
less working-capital build(821)(997)(1,211)(1,472)(1,788)
Free cash flow to firm1,7942,8331,9742,7563,1013,4673,8464,229
Discount factor0.9490.8550.7700.6940.625
Present value2,6162,6522,6712,6692,644
History columns are the filed years (free cash flow there is cash from operations − capex, as filed); the base year and everything to its right come from the engine. Forward is the explicit horizon of the model itself: 3, 5 or 10 years, then flat.

The three statements, projected · ₹ crore · debt held at 14,798, dividends at 59.6% of profit

₹ croreFY26FY27FY28FY29FY30FY31
Income statement
EBIT3,3514,0774,9536,0187,3128,884
Interest at 4.3% on debt(636)(636)(636)(636)(636)
Profit before tax3,4404,3175,3826,6758,248
Profit after tax2,1632,5603,2124,0044,9676,136
Dividends(1,289)(1,525)(1,914)(2,386)(2,960)(3,657)
Balance sheet, year end
Cash1,1171,8742,5873,1943,6073,706
Working capital3,8114,6325,6296,8408,31210,100
Net block and other assets39,38438,84038,42838,22738,34938,941
Debt14,79814,79814,79814,79814,79814,798
Equity17,58518,61919,91721,53423,54126,020
Balance check0000(0)0
Cash flow
From operations3,0983,8664,7995,9327,309
Investing (capex)(815)(1,238)(1,805)(2,559)(3,554)
Financing (dividends)(1,525)(1,914)(2,386)(2,960)(3,657)
Net change in cash75771360741399
Free cash flow to equity2,2832,6272,9933,3733,756
Other liabilities are held at their FY26 level, so the check tests only what the model moves: cash, working capital, net block and other assets, debt and equity. A non-zero check would mean the three statements no longer tie.

Scenarios side by side · ₹ per share

ScenarioTemplateGrowthMarginRateTerminal₹ / sharevs CMP
Base · editingDCF21.5%32%11.00%5%1,285(74.1)%
A scenario is a full set of inputs under a name. Keep Base as the filed history carried forward; add Bull and Bear by saving the current inputs under those names and moving the two or three assumptions you actually hold a view on. The distribution above draws each driver between the lowest and highest value across your scenarios, so three scenarios give it a real range; with one scenario it falls back to fixed bands.